Trade Mark Journal No.2025/045 7 November 2025

WO0000001868627 (1,5,40)

Office of origin: United States of America

Date of International Registration:22 May 2025
Date of designation in the UK: 22 May 2025
Image for mark 1868627 MIMIX

International priority date claimed: 26 November 2024 (United States of America) (98873501)
Class 1
Biological preparations for laboratory, biopharmaceutical processing, and research purposes, namely, reference standards; biological preparations for cancer research; biological preparations for quality control; cell line-derived reference standards for research purpose; samples for use in biochemical or biological laboratory analysis for research purposes; cell line-derived products for scientific and research purposes, including for clinical investigations and for use in product testing; reference standards used for research purposes, namely, next generation sequencing, droplet-digital, real-time pcr or sanger sequencing.
Class 5
Cell line-derived reference standards used in clinical samples; reference standard substances used for clinical tests for medical purposes; reference standards used for next generation sequencing, droplet-digital, real-time pcr or sanger sequencing; reference standards used for detecting chromosomal abnormalities; reference standards used for analysing biological samples.
Class 40
Custom manufacture of cell line-delivered products for medical and commercial applications; custom manufacture of reference standards.

Revvity Health Sciences, Inc.

Representative: Kevin Oliver Revvity, Inc., 77 4th Avenue, Floor 2, Waltham MA 02451, UNITED STATES OF AMERICA